Geneva, Aug. 6 -- International Clinical Trials Registry received information related to the study (ChiCTR2600128509) titled 'A real-world study on the efficacy and safety of roprestine N01 in the treatment of thrombocytopenia caused by concurrent/sequential chemoradiotherapy' on July 21.

Study Type: Interventional study

Study Design: Single arm

Primary Sponsor: Cancer Hospital Chinese Academy of Medical Sciences

Condition: thrombocytopenia related to malignant tumor treatment

Recruitment Status: Not Recruiting

Phase: 4

Date of First Enrollment: 2026-07-21

Target Sample Size: Treatment group:30;

Countries of Recruitment: China

To know more, visit https://www.chictr.org.cn/showproj.html?proj=329674

Disclaimer: Curated by H...